Beacon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Beacon Pharmaceuticals has a total shareholder equity of BDT6.3B and total debt of BDT9.6B, which brings its debt-to-equity ratio to 152.1%. Its total assets and total liabilities are BDT17.8B and BDT11.4B respectively. Beacon Pharmaceuticals's EBIT is BDT1.2B making its interest coverage ratio 1.6. It has cash and short-term investments of BDT1.1B.
Key information
152.1%
Debt to equity ratio
৳9.62b
Debt
Interest coverage ratio | 1.6x |
Cash | ৳1.07b |
Equity | ৳6.32b |
Total liabilities | ৳11.44b |
Total assets | ৳17.76b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BEACONPHAR's short term assets (BDT11.4B) exceed its short term liabilities (BDT9.4B).
Long Term Liabilities: BEACONPHAR's short term assets (BDT11.4B) exceed its long term liabilities (BDT2.1B).
Debt to Equity History and Analysis
Debt Level: BEACONPHAR's net debt to equity ratio (135.1%) is considered high.
Reducing Debt: BEACONPHAR's debt to equity ratio has increased from 58.2% to 152.1% over the past 5 years.
Debt Coverage: BEACONPHAR's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BEACONPHAR's interest payments on its debt are not well covered by EBIT (1.6x coverage).